AbbVie's Rinvoq shows superiority over Humira in head-to-head study

(Reuters) -AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller ...
GlobalData on MSN

FDA approves AbbVie’s Rinvoq for inflammatory bowel disease

The US Food and Drug Administration (FDA) has approved AbbVie’s supplemental new drug application, updating the indication ...

AbbVie Gets Expanded FDA Approval for Rinvoq Drug

The Food & Drug Administration granted AbbVie expanded approval for its Rinvoq drug intended to treat moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease ...
Clinical Pain Advisor

Rinvoq Receives FDA Approval for Updated IBD Indications

The Food and Drug Administration (FDA) has approved updated indications for Rinvoq® (upadacitinib) in the treatment of adults with moderately to severely active ulcerative colitis (UC) or Crohn ...

AbbVie: "Strong Buy" On Rinvoq Expansions And Immunology Pipeline Addition

I rate AbbVie stock as a Strong Buy, based on its FDA approval of Rinvoq. Read the latest analysis on the stock here.
Stocktwits on MSN

AbbVie Stock Rises After FDA Approves Changed Recommendations For Use Of Popular Rinvoq Drug

AbbVie (ABBV) on Monday said that the U.S. Food and Drug Administration has approved an update to the indication statement for its drug Rinvoq for the treatment of adults with moderately to severely ...
The American Journal of Managed Care

FDA Expands Upadacitinib Label for Treating Inflammatory Bowel Disease

The FDA has approved an updated indication for upadacitinib (Rinvoq; AbbVie) in inflammatory bowel disease (IBD), allowing its use in adults with moderately to severely active ulcerative colitis or ...
AOL

Does Medicare Cover Rinvoq?

Doctors prescribe Rinvoq (upadacitinib) to treat certain inflammatory conditions, such as rheumatoid arthritis (RA) and ulcerative colitis (UC). It’s available as an extended-release oral tablet and ...
Morningstar

RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)

NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib), 15 mg, once daily, for the ...

Why AbbVie Stock Soared in September

As in any month, September was eventful for AbbVie. In addition to news about its usual activities, it also scored big with ...
Reuters

AbbVie forecasts 2025 profit above estimates on newer immunology drugs

Skyrizi, Rinvoq sales expected to surpass $31 billion by 2027 Humira sales decline 49% due to cheaper biosimilar competitors AbbVie earns $2.16 per share in Q4, beats estimates Jan 31 (Reuters) - ...

AbbVie's Rinvoq shows superiority over Humira in head-to-head arthritis study

AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira in a ...